暂无摘要。

The China PelvEx Collaborative, under the direction of Colorectal Cancer Committee of the Chinese Medical Doctor Association, Gastrointestinal Surgery Committee of China International Exchange and Promotive Association for Medical and Health, has formulated and issued the Chinese expert consensus for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition) , with the academic support of the Chinese Journal of Gastrointestinal Surgery and Chinese Journal of Colorectal Disease (Electronic Edition). This Consensus refers to the expert consensus developed by the International PelvEx Collaboration, incorporates the latest international multi-center research results and combines the latest research results in China. The Consensus unifies some definitions, clarifies the surgical indications, and puts forward the definition and preventive measures of \"empty pelvic syndrome\" earlier. For the controversial classification of local recurrent rectal cancer, the Chinese classification was proposed for the first time in Consensus. At the same time, the definition of pelvic exenteration is controversial, and a more consistent cognition is proposed. It is believed that, with the in-depth research on complicated rectal cancer, C-PelvEx will gather more higher-level data from clinical research in several domestic centers, so as to further enrich the content of the updated Consensus.
中国盆腔脏器联合切除协作组（C-PelvEx）在中国医师协会结直肠肿瘤专业委员会和中国医疗保健国际交流促进会胃肠外科学分会的指导下，在《中华胃肠外科杂志》和《中华结直肠疾病电子杂志》的学术支持下，制定出台了“超全直肠系膜切除层面的原发性直肠癌和局部复发直肠癌中国专家共识（2023版）”并于2023年第1期本刊发表。本《共识》是在参考了国际PelvEx协作组制定的专家共识及最新国际多中心研究成果、并结合中国最新研究成果而制定的，体现了很强的专业性。《共识》统一规范了部分定义，明确了手术适应证，在国内较早提出了“空盆腔综合征（EPS）”的定义及预防措施。针对存在争议的局部复发性直肠癌分型，《共识》首次提出了中国分型；并对盆腔脏器切除定义存在的争议，提出了目前较为一致的认知。随着对复杂肠癌的深入研究，C-PelvEx将汇聚国内多家中心临床数据，积极开展临床研究以获得更多的、更高级别的临床证据，从而进一步丰富新版《共识》的内容。.

Pelvic exenteration is often required for primary rectal cancer beyond total mesorectal excision (PRC-bTME) and locally recurrent rectal cancer (LRRC). Some patients with radical resection can achieve long-term survival, but they need to face risks, such as huge surgical trauma, serious perioperative complications, permanent loss of organ function and decline in quality of life. Preoperative evaluation of PRC-bTME and LRRC should emphasize multidisciplinary collaboration, and develop individualized diagnosis and treatment strategies. The principles of function preservation and risk-benefit balance in surgery oncology should be followed, and R0 resection should be emphasized. Perioperative complications, surgical trauma and organ function loss should be minimized to achieve the best quality control and balance point. This consensus was formulated by the Colorectal Cancer Committee of the Chinese Medical Doctor Association and the Gastrointestinal Surgery Committee of China International Exchange and Promotive Association for Medical and Health Care. The draft was formed based on the summary of domestic and foreign research progress and expert experience. After discussion, review and modification by experts, an anonymous voting was conducted for each major opinion, and in-depth verification was carried out according to the principles of evidence-based medicine. Finally, the Chinese expert consensus on the pelvic exenteration with primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition) was formed. This consensus mainly summarizes the indications and contraindications of PE for PRC-bTME and LRRC, preoperative diagnosis and evaluation, perioperative treatment, as well as the resection scope, surgical methods, reconstruction of related organs, safety and complications of PE, postoperative follow-up and other issues, in order to provide guidance for PE in patients with PRC-bTME and LRRC.
超全直肠系膜切除层面的原发性直肠癌（PRC-bTME）和局部复发直肠癌（LRRC）患者经盆腔脏器联合切除手术（PE）治疗后，部分患者可获得长期生存，但需要面临巨大手术创伤、围手术期严重并发症、器官功能永久性丧失及生活质量下降等风险。因此，术前评估应强调多学科协作，制定个体化诊疗措施。应遵循肿瘤功能外科原则和手术损伤效益比原则，强调R0根治切除，降低围手术期并发症发生率，减少外科手术创伤及器官功能丧失，以寻找到最佳的质量控制和平衡点。本共识由中国医师协会结直肠肿瘤专业委员会和中国医疗保健国际交流促进会胃肠外科学分会牵头组织，在总结国内外研究进展及专家经验的基础上形成初稿；经专家组成员讨论、审阅与修改，经过对各项主要观点进行无记名投票，并按照循证医学的原则进行深入论证，最终形成《超全直肠系膜切除层面的原发性直肠癌和局部复发直肠癌盆腔脏器联合切除中国专家共识（2023版）》。本共识主要针对PRC-bTME和LRRC施行PE的适应证、禁忌证、术前诊断评估、围手术期治疗以及PE的切除范围、手术方式、相关器官的重建、PE的安全性及其并发症、术后随访等问题进行归纳整理，旨在为PRC-bTME和LRRC规范实施PE手术提供指导意见。.

暂无摘要。

OBJECTIVE: The primary treatment for locally advanced cases of cervical cancer is chemoradiation followed by high-dose brachytherapy. When this treatment fails, pelvic exenteration (PE) is an option in some cases. This study aimed to develop recommendations for the best management of patients with cervical cancer undergoing salvage PE.
METHODS: A questionnaire was administered to all members of the Brazilian Society of Surgical Oncology. Of them, 68 surgeons participated in the study and were divided into 10 working groups. A literature review of studies retrieved from the National Library of Medicine database was carried out on topics chosen by the participants. These topics were indications for curative and palliative PE, preoperative and intraoperative evaluation of tumor resectability, access routes and surgical techniques, PE classification, urinary, vaginal, intestinal, and pelvic floor reconstructions, and postoperative follow-up. To define the level of evidence and strength of each recommendation, an adapted version of the Infectious Diseases Society of America Health Service rating system was used.
RESULTS: Most conducts and management strategies reviewed were strongly recommended by the participants.
CONCLUSIONS: Guidelines outlining strategies for PE in the treatment of persistent or relapsed cervical cancer were developed and are based on the best evidence available in the literature.

BACKGROUND: To determine guidelines for the management of perineal small bowel fistula (PSF) after total or posterior pelvic exenteration.
METHODS: During 15 years, 315 curative pelvic exenterations were performed. PSF occurred in 15 patients (3.5%). We retrieved the precise modality of radiotherapy (fields and doses) and management of all patients (type of surgery, number of surgery and mortality). Delay of occurrence was divided in early (within 30 days or before hospital discharge) and delayed.
RESULTS: All patients underwent surgery. Mortality rate was 13%. Fourteen patients (93%) had history of radiotherapy. No PSF was noted after anterior pelvic exenteration. Higher frequency of PSF was noted after total pelvic exenteration versus posterior pelvic exenteration (P = 0.04). Early PSF occurred in four patients (27%) with higher frequency of small bowel intraoperative injury. Late PSF occurred in 11 patients (73%) divided in small bowel injury in contact with pelvic staples (n = 4) and disease recurrence (n = 6, local recurrence or carcinomatosis). One patient had delayed PSF by ulceration of small bowel in contact with pelvic drain.
CONCLUSIONS: PSF was a life-threatening complication of pelvic exenteration. Radiotherapy leads to weaken small bowel with difficulty of cicatrisation. During pelvic exenteration: (a) extreme careful dissection and interposition of great omentum could avoid small bowel injury, (b) control of pelvic vessels and closure of rectum remnant should not used staplers. Intraoperative management of PSF used successful simple repair in case of early PSF or segmentary resection indeed enlarged to right colon in case of delayed PSF. Postoperative courses had to use intravenous hyperalimentation and digestive tract discharge.

Based on study of 274 cases of prostate cancer treated in our clinic, selection of patient for radical surgical treatment and choice of procedures were discussed. The radical surgical procedures experienced in our clinic were classified as 31 cases of radical prostatectomy, 4 cases of radical cystoprostatectomy and 7 cases of pelvic exenteration. The endocrine therapy was added to non curative cases postoperatively. In the radical prostatectomy group, the 5-year survival rate of patients with stage A and stage B prostatic adenocarcinoma were 100 and 93 per cent, respectively, and 5-year survival rate of patients who had stage C prostatic adenocarcinoma was 75 per cent. The 5-year survival rates of patients with stage C prostatic adenocarcinoma treated by radical cystoprostatectomy and pelvic exenteration were 50 per cent and 66 per cent, respectively. Cancer recurrence has not seen in the bladder in the patients with stage C prostatic adenocarcinoma treated by radical prostatectomy. Operation of urinary diversion had improved the quality of life. From this data, radical prostatectomy would be indicated for the treatment of patients with stage A, stage B and stage C prostatic adenocarcinoma.